Prime Medicine Targets Key Regulatory Milestones as Cash Runway Extends into 2027
Event summary
- Prime Medicine reported $191.4M in cash reserves as of December 31, 2025, providing runway into 2027.
- Plans to file IND/CTA for Wilson Disease program in 1H 2026 and AATD program mid-2026, with initial clinical data expected in 2027.
- PM359 for CGD shows promising Phase 1/2 data; company seeks accelerated FDA approval via BLA submission.
- R&D expenses increased to $160.6M in 2025 from $155.3M in 2024, driven by IP and facility costs.
The big picture
Prime Medicine is advancing its Prime Editing platform across multiple genetic disorders, positioning itself as a leader in next-generation gene therapies. The company's strategic focus on liver-focused programs and ex vivo therapies reflects broader industry trends toward precision medicine and one-time curative treatments. With $191.4M in cash reserves, Prime Medicine aims to sustain its pipeline momentum while navigating regulatory pathways for key programs like PM359.
What we're watching
- Regulatory Alignment
- Whether Prime Medicine can secure FDA alignment for PM359 and achieve accelerated approval.
- Clinical Timelines
- The pace at which Wilson Disease and AATD programs advance through Phase 1/2 trials post-IND/CTA filings.
- Cash Management
- How Prime Medicine balances R&D investments with its $191.4M cash runway into 2027.
Related topics